ID Labs

Quay Tower Closes Over $98 Million in Sales in 2022

Retrieved on: 
Friday, December 9, 2022

RAL Companies and Olivers Realty Group, today announced closings in excess of $98 million in 2022 alone at the coveted Quay Tower, documenting increased year-over-year sales volume and a higher price per square foot in recorded sales than 2021.

Key Points: 
  • RAL Companies and Olivers Realty Group, today announced closings in excess of $98 million in 2022 alone at the coveted Quay Tower, documenting increased year-over-year sales volume and a higher price per square foot in recorded sales than 2021.
  • Quay Tower is a spectacular luxury building offering the last opportunity to own a new construction residence on the Brooklyn Heights waterfront.
  • Quay Tower is home to a 7,433 square-foot penthouse that sold for a record-breaking $20.3 million.
  • Residents at Quay Tower enjoy kitchens with an integrated Gaggenau appliance package, custom white oak cabinetry, and white Princess Quartzite countertops.

NevelHaus, a Category-Defining Home Building Platform, Launches New Collection in Stone Ridge, NY

Retrieved on: 
Wednesday, April 20, 2022

The NevelHaus process eliminates the worry of supply chain issues and uncertainty associated with building from the ground up.

Key Points: 
  • The NevelHaus process eliminates the worry of supply chain issues and uncertainty associated with building from the ground up.
  • We identified an incredible location for a NevelHaus collection that affords both an all encompassing lifestyle for owners with the ability for true customization.
  • Optional elements for buyers include the luxury of an in-ground pool, garage/studio, carport, whole house generator, and solar panels.
  • Stone Ridge features famous stone houses such as the Hasbrouck House and the 1767 Cornelius Wynkoop Stone House, where George Washington once slept.

Biolidics to Commence Commercial Production of its ClearEpi SARS-COV-2 Neutralising Antibody Rapid Test Kit

Retrieved on: 
Wednesday, December 8, 2021

The ClearEpi NAB Test was developed by Biolidics with technology licensed from A*STAR's A*ccelerate.

Key Points: 
  • The ClearEpi NAB Test was developed by Biolidics with technology licensed from A*STAR's A*ccelerate.
  • The clinical validation of the ClearEpi NAB Test was undertaken in Singapore.
  • Biolidics engaged A*STAR Infectious Disease Labs (ID Labs) for the screening of the prototype, as part of the clinical validation of the ClearEpi NAB Test conducted by Biolidics.
  • Most commercially available serology tests against COVID-19, including the Company's COVID-19 Antibody Test Kit launched on 30 March 2020, test for the presence of IgM/IgG antibodies.